MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback